JP2008532014A5 - - Google Patents

Download PDF

Info

Publication number
JP2008532014A5
JP2008532014A5 JP2007557159A JP2007557159A JP2008532014A5 JP 2008532014 A5 JP2008532014 A5 JP 2008532014A5 JP 2007557159 A JP2007557159 A JP 2007557159A JP 2007557159 A JP2007557159 A JP 2007557159A JP 2008532014 A5 JP2008532014 A5 JP 2008532014A5
Authority
JP
Japan
Prior art keywords
useful
epitopes
epitopes according
useful epitopes
nisch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007557159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/006431 external-priority patent/WO2006091734A2/en
Publication of JP2008532014A publication Critical patent/JP2008532014A/ja
Publication of JP2008532014A5 publication Critical patent/JP2008532014A5/ja
Withdrawn legal-status Critical Current

Links

JP2007557159A 2005-02-24 2006-02-24 生物試料を分類するための組成物及び方法 Withdrawn JP2008532014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65685905P 2005-02-24 2005-02-24
PCT/US2006/006431 WO2006091734A2 (en) 2005-02-24 2006-02-24 Compositions and methods for classifying biological samples

Publications (2)

Publication Number Publication Date
JP2008532014A JP2008532014A (ja) 2008-08-14
JP2008532014A5 true JP2008532014A5 (enExample) 2009-04-16

Family

ID=36928007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557159A Withdrawn JP2008532014A (ja) 2005-02-24 2006-02-24 生物試料を分類するための組成物及び方法

Country Status (11)

Country Link
US (1) US20090075832A1 (enExample)
EP (1) EP1859266A4 (enExample)
JP (1) JP2008532014A (enExample)
KR (1) KR20080003321A (enExample)
CN (1) CN101160524A (enExample)
AU (1) AU2006216683A1 (enExample)
CA (1) CA2598889A1 (enExample)
IL (1) IL185458A0 (enExample)
MX (1) MX2007010349A (enExample)
RU (1) RU2007135030A (enExample)
WO (1) WO2006091734A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009029716A1 (en) * 2007-08-28 2009-03-05 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
TWI466680B (zh) * 2008-08-01 2015-01-01 Oncotherapy Science Inc Melk抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB0823366D0 (en) * 2008-12-22 2009-01-28 Uni I Oslo Synthesis
KR101067815B1 (ko) * 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之melk胜肽及含此胜肽之疫苗
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
WO2013026807A1 (de) * 2011-08-19 2013-02-28 Protagen Ag Neues verfahren zur diagnostik von hochaffinen bindern und markersequenzen
WO2013031757A1 (ja) * 2011-08-29 2013-03-07 東レ株式会社 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
US20130183242A1 (en) * 2012-01-18 2013-07-18 University Of Connecticut Methods for identifying tumor-specific polypeptides
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015172843A1 (en) * 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
EP3145516A4 (en) * 2014-05-20 2018-06-13 Kiromic, LLC Methods and compositions for treating malignancies with dendritic cells
WO2016118733A1 (en) 2015-01-21 2016-07-28 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
MX393605B (es) 2015-06-26 2025-03-24 Univ California Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo
HUE051896T2 (hu) 2015-07-16 2021-03-29 Inhibrx Inc Multivalens és multispecifikus DR5-kötõ fúziós fehérjék
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
SI3573647T1 (sl) * 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原短肽的tcr及其相关组合物
EP3756680A1 (en) * 2019-06-26 2020-12-30 Universitat de Lleida Intermediate filament-derived peptides and their uses
EP3999525A4 (en) * 2019-07-15 2023-08-09 Geisinger Health System COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST CANCER WITH A NOVEL CAPER ALPHA MLL1 COMPLEX
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN116773798A (zh) * 2023-06-16 2023-09-19 北京三品医疗科技有限公司 多肽的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
AU2002226912A1 (en) * 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2002302410A1 (en) * 2001-03-10 2002-09-24 Affina Immuntechnik Gmbh Method for identifying immune reactive epitopes on proteins
EP2302387A1 (en) * 2001-04-10 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles for insulin-dependent diabetes mellitus
WO2003042357A2 (en) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
AU2002360082A1 (en) * 2002-12-23 2004-07-22 Peter Lorenz Human autoantigens and use thereof
AU2003300368A1 (en) * 2002-12-26 2004-07-29 Cemines, Llc. Methods and compositions for the diagnosis, prognosis, and treatment of cancer

Similar Documents

Publication Publication Date Title
JP2008532014A5 (enExample)
RU2007135030A (ru) Композиции и способы классификации биологических образцов
JP7531217B2 (ja) 癌を査定および/または処置するためのセルフリーdna
Borie et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma
van Buuren et al. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection
Landt et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia
Hasan et al. Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers
CN103826750B (zh) 从血液中捕获和检测循环多发性骨髓瘤的测定法
JP2012508865A5 (enExample)
JP2009538607A5 (enExample)
Mok et al. Association of kidney disease measures with cause-specific mortality: the Korean Heart Study
JP2009522578A5 (enExample)
Lu et al. Predictors of discordant tuberculin skin test and QuantiFERON-TB gold in-tube results in eastern China: a population-based, cohort study
Los-de Vries et al. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
Batistatou et al. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays
JP2015518152A (ja) 前立腺がんの検出用バイオマーカーの定量
EP3022561A1 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
JP2008502332A5 (enExample)
JP2007508527A5 (enExample)
Catlett et al. Primary lymphoma of bone: an institutional experience
Huang et al. Aneuploid circulating tumor cells as a predictor of response to neoadjuvant chemotherapy in non-small cell lung cancer
JP2016531596A (ja) 循環している癌のバイオマーカー及びその使用
JP2010526995A5 (enExample)
Benhammou et al. DETECT: development of technologies for early HCC detection
Maeshima et al. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients